Fumarate hydratase (FH)-deficient renal cell carcinoma (RCC) is rare and highly aggressive and is believed to arise mostly in the setting of hereditary leiomyomatosis-RCC syndrome with a germline mutation of FH. Because of the aggressiveness of these tumors and a frequent lack of ascertainable family history, these tumors may first present as metastases and be sampled by cytology. The cytologic findings of FH-deficient RCC have not previously been reported. METHODS: Cytologic and limited biopsy samples from patients with FH-deficient RCC were reviewed retrospectively. RESULTS: In total, 24 cytologic and limited biopsy samples from 19 patients (6 women and 13 men; age range, 22-69 years) who had FH-deficient RCC and metastasis at presentation were evaluated. These included 21 cytology samples ranging from malignant effusions (n = 7) to metastases (n = 11), to samples of primary kidney tumors (n = 3). The samples exhibited cells, often in clusters and abortive papillae, with voluminous, finely vacuolated cytoplasm and large, pleomorphic nuclei with prominent, viral inclusion-like nucleoli. A distinctive finding of peripheral cytoplasmic clearing frequently was apparent, and intranuclear cytoplasmic pseudoinclusions were less frequent. Of 7 cell block and biopsy samples, several of which represented sampling from the same patient, all demonstrated tissue fragments that had discernable morphologic patterns associated with FH-deficient RCC, including tubulocystic and intracystic papillary growth. CONCLUSIONS: Features characteristic and suggestive of FH-deficient RCC may be identified in cytologic and small biopsy samples. Although the current samples were identified retrospectively in well characterized cases of FH-deficient RCC, the authors argue that, with appropriate clinical correlation, these features are sufficiently distinctive to trigger recognition and confirmatory workup. Cancer Cytopathol 2018;126:992-1002.
INTRODUCTION
Hereditary leiomyomatosis-renal cell carcinoma (HLRCC) syndrome is an autosomal dominantly inherited, neoplastic diathesis characterized by a penetrant (approximately ≥80%) phenotype of uterocutaneous Cancer Cytopathology December 2018 leiomyomatosis, with a less penetrant phenotype (approximately 5%-20%; varies according to the cohort studied) of high-grade renal cell carcinoma (RCC). 1 Affected individuals harbor germline mutations or deletions of the fumarate hydratase (FH) gene located on chromosome 1q42.3-q43. 2 The RCCs arising in this syndrome exhibit variable morphology with a high multiplicity of patterns 3 and arise across a wide age range. However, in contradistinction to several other hereditary RCC syndromes, with few exceptions, 4, 5 these tumors tend to have highgrade morphology and an aggressive clinical course. 6 Despite the wide variation in architectural patterns described in these RCCs, including papillary, tubulopapillary, solid, cribriform, and cystic patterns, sections of these tumors tend to exhibit a striking, viral inclusion-like, orangeophilic macronucleolus with a perinucleolar halo of clearing. 6 Now an accepted entity in the World Health Organization classification, 7 increasing scholarship has confirmed the broad morphologic range 8, 9 and relatively frequent tubulocystic pattern, 10 which appears to be a useful morphologic marker for differentiation from other high-grade, infiltrative renal tumors.
11
Most relevant to prospective diagnostic practice, recent reports have established the utility of immunohistochemistry for FH 8, 12 and antibodies detecting aberrant succination (anti-S-[2-succino]-cysteine [2SC]) 9 for the recognition of this tumors. On the basis of experience with FH and 2SC in the workup of kidney tumors, noting many cases with immunohistochemical and morphologic findings suggestive of HLRCC syndrome but nearly always without available data on stigmata, family history, or genetic testing at the time of sign out, we recently proposed the term FH-deficient RCC as a provisional diagnostic term 10 to phenotypically label cases. This term avoids appearing to diagnose a genetic syndrome without appropriate workup and is amenable to (likely rare) sporadic, nonsyndromic cases of FH-deficient RCC occurring by somatic mutation only. 10, 13 The term is to be used with a recommendation of genetic counseling and testing, which is frequently positive in such cases. 3 One remarkable aspect of FH-deficient RCC is its aggressive behavior, with a high potential to metastasize early, 6 mostly at the time of presentation. 9, 10 For this reason, these tumors initially may be sampled by fine-needle aspiration (FNA) or by core biopsy to establish a tissue diagnosis for treatment planning. The features of FH-deficient RCC in cytologic samples have not been characterized; therefore, to aid in the prospective recognition of this entity, we assembled and studied a cohort of cytologic samples from well characterized cases.
MATERIALS AND METHODS
This was a retrospective clinicopathologic, morphologic, and cytologic analysis of 21 cytology samples from 18 patients who had FH-deficient RCC confirmed by immunohistochemistry (FH-negative and/or 2SC-positive; N = 7; including 1 with an FH deletion identified in somatic tumor sequencing) or who had a germline FH mutation (N = 12). We also reviewed 3 small metastatic biopsy samples, including 2 from patients who had cytology preparations available, as listed in Table 1 , and an additional metastasis biopsy sample (see Table 2 , patient 8) 10, 14 for which there were no cytology preparations. Cases were identified by retrospective searches of pathology databases from 3 institutions with the approval of each institutional review board. The nephrectomy surgical pathology aspects of 5 of the FH-deficient RCCs have been described in detail in prior studies, 9, 10 an additional case was described as a case report 14 without any review of associated cytologic or metastatic samples. Deidentified clinicopathologic data were collected through a review of patient medical records and surgical pathology reports. FH and 2SC immunostaining protocols have been previously reported. 4, 10 All cytologic slides were re-reviewed, and their features were tabulated by multiple genitourinary surgical pathologists (L.C., S.C.S., and A.J.G.) and cytopathologists (L.M., V.R., X.W., and O.L.).
RESULTS

Clinicopathologic Features of FH-Deficient RCCs
In total, 19 patients, including 6 women and 13 men (age range, 22-69 years; median age, 45 years) were identified. Twelve patients (63%) had germline FH mutations, whereas 7 had FH-deficient RCC based on FH-deficient immunophenotype and/or somatic sequencing. Stigmata associated with HLRCC syndrome included 5 patients with uterine leiomyomata (including 2 without germline mutation data) and 1 with cutaneous leiomyomata. Potential family history documented included a family history of RCC (N = 3), cutaneous leiomyoma (N = 1) This preparation was performed on a surgical specimen.
c NA indicates that data were not available for specimens that did not include a DQ preparation. LG, E, CW This patient underwent core biopsy only, without a touch or other cytologic preparation, and thus is not listed in Table 1 .
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and "skin rash" (N = 1). Table 2 summarizes the clinical findings for each patient. Primary tumors ranged in size from 2.5 to 21.5 cm (median, 11.6 cm); 4 tumors were pathologically staged as pT4, 8 tumors were staged as pT3, 2 were staged as pT2, and 1 was staged as pT1. Three patients had advanced disease identified on imaging studies and did not undergo cytoreductive nephrectomy. The disease course was uniformly aggressive; 6 patients were dead of disease at <18 months (of which 5 had progressive, diffusely metastatic disease), and 6 were dead of disease between 18 and 64 months. All patients had lymph node or visceral metastatic disease at presentation. Figure 1 presents representative examples of imaging and histopathologic findings.
Findings in Cytologic Samples
In total, 21 cytologic samples corresponding to 18 patients were identified and reviewed retrospectively, sampling 7 malignant effusions (5 pleural, 2 ascites), 5 lymph nodes, 6 metastases (3 liver metastases and 1 each adrenal, chest wall, and pleural metastases), and 3 primary kidney tumors. Table 1 details the samples and the preparation types reviewed.
Cytologic preparations most frequently were cellular (n = 9) or moderately cellular (n = 7) rather than low in cellularity (n = 4), and the hypocellular samples corresponded to effusion samples in 3 of 4 preparations. All cases demonstrated striking, markedly enlarged, malignant cells with abundant, voluminous cytoplasm, nearly all of which presented at least focally in well defined, 3-dimensional clusters (20 of 21 cases; 95%) ( Fig. 2A) or papillae (15 of 21 cases; 71%) (Fig. 2B,C Findings that we deemed distinctive upon review were observed most prominently in Diff-Quik-stained preparations, including frequent peripheral clearing of cytoplasm, imparting a 2-toned appearance with paler cytoplasm toward the cell membrane (15 of 17 cases; 88%) (Fig. 3A,B) . In addition, most prominent in 
Cancer Cytopathology December 2018
Papanicolaou (Pap)-stained preparations (but less prevalent overall) were intranuclear cytoplasmic pseudoinclusions (6 of 21 cases; 29%) (Fig. 3C) . Cytologic features that echoed those described in surgical pathology specimens for FH-deficient RCCs were prevalent, including enlarged, pleomorphic nuclei ( 
Findings in Routine Sections From Biopsies and FNA Cell Blocks
In total, 11 samples processed for hematoxylin and eosin-stained sections were reviewed (10 from cytology samples and 1 additional metastasis core biopsy). These included FNA cell blocks (n = 3: kidney tumor, liver metastasis, and supraclavicular lymph node metastasis), core-needle biopsies (n = 6: kidney tumor, liver and adrenal metastasis), and small surgical biopsies (n = 2: lymph node metastasis and chest wall metastasis). The samples from primary renal tumors demonstrated various solid, tubular, papillary, and tubulocystic patterns in 2 cases (cores), and 1 fragment exhibited an intracystic papillary pattern with a hyalinized fibrovascular core in an FNA cell block from another case (Fig. 4A,B) . The liver metastasis FNA cell block demonstrated scattered papillary fragments only, whereas 3 liver metastasis core biopsies exhibited tubulocystic, papillary, and focally cribriform patterns (Fig. 4C ). An adrenal cortical metastasis core biopsy had a solid pattern. Two additional, small surgical biopsies were reviewed, including a supraclavicular lymph node resection, which had an extensive papillary pattern (Fig. 4D) , and a chest wall metastasis, which had an infiltrative tubular and nested pattern. Intraoperative frozen sections from this chest wall lesion had been prepared and revealed features similar to those observed in (C) In a subset of cases (particularly touch preparations from core biopsy samples), exaggerated, large papillary structures with copious, metachromatic stroma were apparent and were deemed to represent papillae with hyalinized cores, a feature strongly associated with fumarate hydratase-deficient renal cell carcinoma in surgical specimens. 10 (D) At higher power magnification, the sampled cells exhibited significant pleomorphism, often with eccentric nuclei, and prominent nuclei were apparent in DiffQuik stains. Frequently, the cytoplasm had fine vacuolation.
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DISCUSSION
FH-deficient RCCs, including those occurring in the syndromal setting of HLRCC, are aggressive tumors that frequently present with metastatic disease. 6 For this reason, such tumors frequently may be sampled for initial diagnosis by aspiration cytology or core biopsy, or for confirmation of metastatic progression postresection. Although contemporary immunohistochemistry, including such markers as paired box gene 8 (PAX8), with correlation to imaging findings of a dominant renal mass, can help establish a renal primary origin, 15 cytologic and rudimentary architectural features can provide important clues for the subclassification of RCC. Nonetheless, cytologic features of FH-deficient RCC have not been reviewed systematically, and, in our experience, these tumors remain under-recognized in both cytology and surgical pathology. Indeed, several of the older cases described herein originally had been designated as unclassified "type 2" papillary or were described as mixed RCC with clear and granular cell features. Given the emphasis on distinguishing between clear cell and nonclear cell RCC under current practice guidelines, the emerging clinical trial options for patients who have HLRCC syndrome, and the need for genetics consultation and surveillance among affected kindreds, we undertook the current retrospective review of the features of any cytologic and small biopsy samples taken during the diagnostic workup and management of these patients. The overall findings in this cohort document that recognizable morphologic features related to those described for surgical pathology specimens of FH-deficient RCC may be observed in cytology specimens, and several additional, striking or distinctive cytologic features also may be identified. In the case of the former, the presence of markedly enlarged and pleomorphic nuclei with striking, cytomegalovirus inclusion-like macronuclei were noted in every case, if variously prominent in Cancer Cytopathology December 2018 any individual case. What was noted much less, and then only in Pap-stained preparations or in cell block material, was the characteristic (and more specific) feature of a perinucleolar halo of pallor in the nucleoplasm. Also reminiscent of histopathologic features was the formation of clusters, often cohesive with a 3-dimensional appearance, in direct smear samples.
However, 2 additional, distinctive cytologic features were identified. The first feature was voluminous, abundant cytoplasm in the neoplastic cells. Second, there was frequently a "2-toned" or variegated appearance, in which the most peripheral aspect of the cytoplasm, approaching the plasma membrane, demonstrated lighter staining or clearing compared with that observed in more central areas of Diff-Quik preparations. Characteristically (but not specifically), cytoplasmic vacuolation was apparent, usually as fine vacuolation with small vesicles. Less prevalent was the appearance of intranuclear cytoplasmic pseudoinclusions, reminiscent of papillary thyroid carcinoma, in Pap-stained slides from a subset of cases. Helpfully, when available, scant samples taken from metastases demonstrated architectural features that have been described as characteristic of [8] [9] [10] and, in our recent comparative studies, distinctive for 19 FH-deficient RCCs, particularly with tubulocystic and intracystic papillary pattern, the latter with hyalinization of fibrovascular cores.
The differential diagnosis on cytologic grounds of a metastatic tumor in the setting of a suspected renal primary must focus on the most common and clinically actionable (under practice guidelines) entity in this differential, conventional clear cell RCC. Similar to findings from the FH-deficient tumors described herein, clear cell RCC cytology samples frequently have clustered cells with abundant cytoplasm (often finely vacuolated) and eccentric nuclei. 16 Although they vary across World Health
Organization/International Society of Urologic Pathology grades, nucleoli tend to be less prominent even in grade 3 and 4 conventional clear cell tumors compared with the remarkable, viral inclusion-like appearance in FH-deficient RCC samples. Whereas comprehensive studies of FHdeficient RCC immunophenotypes have not been performed, we emphasize that these tumors share positivity for PAX8 and, at least anecdotally, for CA-IX (carbonic anhydrase IX) 3, 17 with clear cell RCC, indicating the importance of correlations with any syndromal concerns and cytologic and morphologic features. We note that Xp11-translocation RCCs often exhibit abundant, voluminous cytoplasm in cytologic samples. 18 Although decreased expression of pancytokeratins and melanocytic markers in translocation RCCs is characteristic and distinctive from FH-deficient RCCs (and other RCC types), 18, 19 these features are neither sufficiently sensitive nor specific to establish reliably the diagnosis of translocation RCC. Because the available antibodies against transcription factor E3 (TFE3) and transcription factor EB (TFEB) often are technically challenging, contemporary workup emphasizes the use of break-apart fluorescence in situ hybridization for the TFE3 locus (or the TFEB locus for the less common t [6, 11] translocation RCCs) as a definitive molecular test. 20 Given the frequent clustering and papillary architecture observed in most of our samples, the cytologic differential with conventional papillary RCC deserves mention. Although the presence of true fibrovascular cores may be shared, in no case of FH-deficient RCC did we observe distention of cores with foamy macrophages, nor was the characteristic monomorphous appearance of conventional papillary RCC cytology 16, 21 or clear cell papillary RCC 22 of the referral institutions of the contributors. However, given the rarity of these tumors, such biases were necessary to assemble sufficient numbers for retrospective characterization. Challenging, too, remains the overall genetic interpretation of several cases of FH-deficient RCC retrieved from the files, for which data on neither syndromal stigmata nor genetic testing are available. Although we note that cases of FH-deficient RCC arising apparently by somatic mutation only have been identified, 10, 13 the degree of specificity of the FH-deficient phenotype for bona fide HLRCC syndrome with a germline FH mutation remains a principal unanswered question in the field. Increasingly, we argue that the recognition (whether based on cytologic, histomorphologic, or immunophenotypic features) of these tumors is a pathologist's responsibility, 1 so that genetic counseling and testing may be undertaken. A recent study has documented relatively high rates of positive genetic testing for patients who were referred based on suspicious kidney tumor pathology. 27 Recent data also suggest that features like syndromal stigmata and family history should not be considered useful predictors of testing positive for RCC-predisposing syndromes (only young age had a significant association). 28 In summary, our current review of cytologic findings from cases of FH-deficient RCC has identified several features that, taken together, we believe will be sufficiently distinctive to enable the prospective recognition of these cases. Although much work remains to be done with regard to delineating the genetics of these tumors and discovering therapeutic angles, the recognition of these cases remains the first step.
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